The stock of ImmuPharma PLC (LON:IMM) is a huge mover today! The stock decreased 1.27% or GBX 0.5 on November 23, hitting GBX 38.75. About 175,600 shares traded hands. ImmuPharma PLC (LON:IMM) has risen 55.45% since April 25, 2016 and is uptrending. It has outperformed by 50.12% the S&P500.
The move comes after 8 months positive chart setup for the GBX 45.95M company. It was reported on Nov, 23 by Barchart.com. We have GBX 39.91 PT which if reached, will make LON:IMM worth GBX 1.38M more.
ImmuPharma PLC (LON:IMM) Ratings Coverage
Out of 2 analysts covering ImmuPharma PLC (LON:IMM), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. GBX 171 is the highest target while GBX 100 is the lowest. The GBX 135.50 average target is 249.68% above today’s (GBX 38.75) stock price. ImmuPharma PLC has been the topic of 16 analyst reports since September 30, 2015 according to StockzIntelligence Inc. The stock of ImmuPharma PLC (LON:IMM) earned “Buy” rating by Panmure Gordon on Monday, December 7. As per Friday, September 30, the company rating was maintained by Panmure Gordon. The stock has “Corporate” rating given by Northland Capital on Monday, June 20. Panmure Gordon maintained the shares of IMM in a report on Tuesday, June 14 with “Buy” rating. The firm earned “Buy” rating on Monday, October 24 by Northland Capital. As per Wednesday, November 9, the company rating was maintained by Northland Capital. The firm has “Buy” rating by Panmure Gordon given on Wednesday, November 4. Panmure Gordon maintained ImmuPharma PLC (LON:IMM) on Monday, October 24 with “Buy” rating. On Wednesday, September 14 the stock rating was maintained by Northland Capital with “Corporate”. The rating was maintained by Panmure Gordon on Wednesday, September 14 with “Buy”.
ImmuPharma plc is a drug discovery and development company. The company has a market cap of 45.95 million GBP. The Firm is focused on the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases. It currently has negative earnings. The Firm has approximately five drug candidates in development, over two platform technologies and approximately 70 patents.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.